Phase I Trial of Intratumoral Administration of NIS-Expressing Strain of Measles Virus in Unresectable or Recurrent Malignant Peripheral Nerve Sheath Tumor
Technical Report,15 Sep 2016,14 Sep 2017
Mayo Clinic And Foundation Rochester United States
Pagination or Media Count:
Study approved by Mayo IRB on April 18, 2016, and by USAMRMCORPHRPO on May 6, 2016. All study staff completed IRB training. Dose volume charts have been developed to facilitate pharmacy orders. Study opened for enrollment on May 17, 2016. Study coordinators identified and assigned to the study by Mayo Clinic Cancer Center. Three patients have been enrolled in the study. They completed treatment per protocol and continue the follow up. None of the treated patients experienced side effects. With the first 3 patients we have completed the first dose level. We are continuing recruitment for the second dose level.
- Medicine and Medical Research
- Genetic Engineering and Molecular Biology